Show simple item record

dc.contributor.authorHudson, L
dc.contributor.authorMui, J
dc.contributor.authorVázquez, S
dc.contributor.authorCarvalho, DM
dc.contributor.authorWilliams, E
dc.contributor.authorJones, C
dc.contributor.authorBullock, AN
dc.contributor.authorHoelder, S
dc.date.accessioned2020-11-17T11:09:15Z
dc.date.issued2018-08-23
dc.identifier.citationJournal of medicinal chemistry, 2018, 61 (16), pp. 7261 - 7272
dc.identifier.issn0022-2623
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4232
dc.identifier.eissn1520-4804
dc.identifier.doi10.1021/acs.jmedchem.8b00782
dc.description.abstractStructure-activity relationship and crystallographic data revealed that quinazolinone-containing fragments flip between two distinct modes of binding to activin receptor-like kinase-2 (ALK2). We explored both binding modes to discover potent inhibitors and characterized the chemical modifications that triggered the flip in binding mode. We report kinase selectivity and demonstrate that compounds of this series modulate ALK2 in cancer cells. These inhibitors are attractive starting points for the discovery of more advanced ALK2 inhibitors.
dc.formatPrint-Electronic
dc.format.extent7261 - 7272
dc.languageeng
dc.language.isoeng
dc.publisherAMER CHEMICAL SOC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectCell Line
dc.subjectHumans
dc.subjectActivin Receptors, Type I
dc.subjectProtein Kinase Inhibitors
dc.subjectCrystallography, X-Ray
dc.subjectDrug Evaluation, Preclinical
dc.subjectStructure-Activity Relationship
dc.subjectDose-Response Relationship, Drug
dc.subjectQuinazolinones
dc.titleNovel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept.
dc.typeJournal Article
dcterms.dateAccepted2018-08-07
rioxxterms.versionofrecord10.1021/acs.jmedchem.8b00782
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-08-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of medicinal chemistry
pubs.issue16
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 4 (including Analytical Chemistry)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 4 (including Analytical Chemistry)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team
pubs.publication-statusPublished
pubs.volume61
pubs.embargo.termsNot known
icr.researchteamMedicinal Chemistry 4 (including Analytical Chemistry)
icr.researchteamGlioma Team
dc.contributor.icrauthorJones, Chris
dc.contributor.icrauthorHoelder, Swen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0